Please assess the completion status of the following clinical trial:

Trial Title: Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Main criteria:~* Postmenopausal women (hysterectomized or not)~* Women between 40 and 80 years of age~* Women having ≤5% of superficial cells on vaginal smear at baseline~* Women having a vaginal pH above 5 at baseline~* Women who have self-identified moderate or severe symptom(s) of vaginal atrophy~* Willing to participate in the study and sign an informed consent~Exclusion Criteria:~Main criteria:~* Previous enrollment in EndoCeutics studies performed with intravaginal DHEA~* Previous diagnosis of cancer, except skin cancer (non melanoma)~* Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication~* The administration of any investigational drug within 30 days of screening visit~* Clinically significant abnormal serum biochemistry, urinalysis or hematology

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaginal ovule daily for 12 weeks
- Prasterone (Type: EXPERIMENTAL): Prasterone (DHEA) vaginal ovule daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).